Will the patient pay in Europe?
This article was originally published in Clinica
As cost-containment pressures continue unabated in Europe, it is becoming increasingly likely that patients will have to contribute towards the costs of any medical devices they may need. This may provide a marketing opportunity for the industry, says Thomas Seeger, principal consultant of the strategic reimbursement and pricing division at MTC in Germany.
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”